Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroprotective Effects of Methylphenidate and Atomoxetine in ADHD
NCT03936491Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methylphenidate hydrochloride extended-release chewable tablet and atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: ADHD Rating Scale-IV-Parent version at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletatomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03936491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936491.